Aspen Aerogels, Inc. (NYSE:ASPN) Shares Purchased by Algert Global LLC

Algert Global LLC boosted its stake in Aspen Aerogels, Inc. (NYSE:ASPN) by 57.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 79,757 shares of the construction company’s stock after purchasing an additional 29,223 shares during the period. Algert Global LLC owned about 0.10% of Aspen Aerogels worth $1,902,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Driehaus Capital Management LLC grew its stake in shares of Aspen Aerogels by 130.4% in the second quarter. Driehaus Capital Management LLC now owns 2,156,789 shares of the construction company’s stock worth $51,439,000 after acquiring an additional 1,220,724 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Aspen Aerogels by 34.4% in the second quarter. The Manufacturers Life Insurance Company now owns 26,003 shares of the construction company’s stock worth $620,000 after acquiring an additional 6,653 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Aspen Aerogels in the second quarter worth $9,339,000. Alpha DNA Investment Management LLC acquired a new position in shares of Aspen Aerogels in the second quarter worth $398,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Aspen Aerogels in the second quarter worth $84,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity at Aspen Aerogels

In related news, CEO Donald R. Young sold 63,355 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $30.03, for a total value of $1,902,550.65. Following the completion of the sale, the chief executive officer now directly owns 483,640 shares of the company’s stock, valued at $14,523,709.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CFO Ricardo C. Rodriguez sold 32,465 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $30.14, for a total value of $978,495.10. Following the completion of the sale, the chief financial officer now directly owns 20,790 shares of the company’s stock, valued at $626,610.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the completion of the sale, the chief executive officer now directly owns 483,640 shares of the company’s stock, valued at $14,523,709.20. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

Aspen Aerogels Price Performance

Shares of ASPN opened at $25.01 on Thursday. Aspen Aerogels, Inc. has a 1-year low of $6.62 and a 1-year high of $33.15. The stock has a market cap of $1.90 billion, a PE ratio of -56.83 and a beta of 2.16. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.46 and a quick ratio of 2.82. The firm has a fifty day moving average price of $25.28 and a 200 day moving average price of $23.81.

Aspen Aerogels (NYSE:ASPN) last announced its quarterly earnings results on Wednesday, August 7th. The construction company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.16. Aspen Aerogels had a net margin of 0.39% and a return on equity of 0.74%. The firm had revenue of $117.80 million during the quarter, compared to analysts’ expectations of $101.99 million. During the same period in the previous year, the company earned ($0.22) earnings per share. Aspen Aerogels’s quarterly revenue was up 144.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Aspen Aerogels, Inc. will post 0.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. TD Cowen boosted their price target on shares of Aspen Aerogels from $36.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, August 20th. Barclays assumed coverage on shares of Aspen Aerogels in a research note on Tuesday, August 6th. They issued an “overweight” rating and a $27.00 price target for the company. Benchmark restated a “buy” rating and issued a $14.00 price target on shares of Aspen Aerogels in a research note on Thursday, August 8th. Roth Mkm reiterated a “buy” rating and set a $36.00 target price on shares of Aspen Aerogels in a research note on Wednesday, August 21st. Finally, Craig Hallum boosted their target price on shares of Aspen Aerogels from $33.00 to $38.00 and gave the stock a “buy” rating in a research note on Friday, June 14th. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.70.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.